Mar 07,2019

Tandem Diabetes Care Approved as Insulin Pump Vendor for ADP in Ontario, Canada

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today announced that it is now registered as an approved vendor of insulin pumps and supplies under the Assistive Devices Program (ADP) in Ontario, Canada. The t:slim X2 insulin pump features Dexcom G5® Mobile continuous glucose monitoring (CGM) integration, making it the only CGM-integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 12,2019

Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region

Nemaura Medical, Inc., a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has signed an exclusive license and supply agreement for SugarBEAT® with TPMENA in the Gulf Cooperation Council (GCC) Region, which includes Bahrain, Kuwait, Saudi Arabia, Oman and United Arab Emirates.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 08,2019

New Value-Based Agreement Between Blue Cross and Blue Shield of Minnesota and Medtronic Leverages Diabetes Technology to Drive Positive Outcomes

Blue Cross and Blue Shield of Minnesota and Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, announce a new outcomes-based agreement that provides members of the Blue Cross and Blue Shield of Minnesota plan who live with diabetes improved access to the Guardian(TM) Connect smart Continuous Glucose Monitoring (CGM) system. The system will also now be made available through a member's pharmacy benefit, improving speed of delivery and may lower costs for members who use the device. Using the amount of time spent in a healthy glucose range as a key metric, value-based payments will be tied to the percentage of Time in Range achieved using the Guardian Connect system.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 18,2019

Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®

Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has incorporated new predictive alert functionality into SugarBEAT®.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 23,2019

Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®

Nemaura Medical, Inc., a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,’ in preparation for submission of its medical device application to the FDA for SugarBEAT®.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 07,2019

Senseonics scores coveted non-adjunctive labeling claim for Eversense CGM

Implantable CGM company Senseonics has received approval from the FDA for the non-adjunctive indication for its Eversense device.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 08,2019

NEW DATA SHOW USE OF ABBOTT'S FREESTYLE® LIBRE SYSTEM SIGNIFICANTLY REDUCES HBA1C LEVELS IN PEOPLE LIVING WITH TYPE 2 DIABETES

Presented as a late-breaker at the American Diabetes Association (ADA) 79th Scientific Sessions, new real-world data demonstrate that monitoring glucose with FreeStyle Libre System has a positive impact among adults with Type 2 Diabetes who use multiple injections of insulin daily.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 06,2019

Dexcom and Companion Medical Announce Collaboration to Integrate Dexcom CGM Data and InPen™ Insulin Data

DexCom, Inc. and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. This agreement is the first of its kind and paves the way for advanced diabetes decision support, an important tool for insulin users.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 08,2019

Medtronic Initiates Pivotal Trial for Next-Generation Guardian(TM) Continuous Glucose Monitoring Sensor

Medtronic plc, the global leader in medical technology, today announced that it has initiated the company's pivotal trial for its next-generation Guardian(TM) continuous glucose monitoring (CGM) sensor designed to improve accuracy and overall system performance, reduce sensor calibrations and enhance overall user experience.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 10,2019

Real-World Data from Guardian(TM) Connect and Sugar.IQ(TM) Reveal Improved Diabetes Outcomes

Medtronic plc, the global leader in medical technology, today announced real-world data on its Guardian(TM) Connect continuous glucose monitoring (CGM) system and Sugar.IQ(TM) diabetes assistant app presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) Annual Meeting in San Francisco. The data found that people using the Guardian Connect system with the Sugar.IQ app experienced 4.1% more Time in Range (63.4%) compared to Guardian Connect alone (59.3%) which represents about one extra hour per day.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM